Sandoz Canada receives Health Canada approval for Erelzi (etanercept) in the treatment of psoriatic arthritis in adult patients

21 January 2019 - Erelzi is the only etanercept biosimilar to be indicated for reducing the signs and symptoms of psoriatic ...

Read more →

Valeo Pharma and Zambon announce the approval of Onstryv (safinamide) for Canada

15 January 2019 - New treatment option for estimated 100,000 Canadians living with Parkinson's disease. ...

Read more →

Health Canada restricts Allergan's Esmya

15 January 2019 - Health Canada has placed restrictions on Allergan's uterine fibroid treatment Esmya, after discovering a possible link ...

Read more →

Health Canada approves Xtandi (enzalutamide) - the first and only oral treatment for men with non-metastatic and metastatic castration-resistant prostate cancer

14 January 2019 - Astellas today announced that Health Canada approved an expanded indication for enzalutamide, an androgen receptor inhibitor for ...

Read more →

Bausch & Lomb announces Health Canada approval of Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%) for the treatment of glaucoma

3 January 2019 - Bausch & Lomb today announced that on 27 December 2018, Health Canada issued the notice of compliance ...

Read more →

Cipher Pharmaceuticals announces A-101 40% topical solution accepted for review by Health Canada

18 December 2018 - Cipher Pharmaceuticals today announced that its new drug submission for A-101 40% topical solution ("A-101 40%") ...

Read more →

Cipher Pharmaceuticals announces plecanatide accepted for review by Health Canada

17 December 2018 - Cipher Pharmaceuticals today announced that its new drug submission for plecanatide for irritable bowel syndrome with ...

Read more →

Emergent BioSolutions receives Health Canada approval of BioThrax (anthrax vaccine adsorbed)

17 December 2018 - Emergent BioSolutions today announced that Health Canada has approved the company’s new drug submission for its anthrax ...

Read more →

Health Canada approves Darzalex (daratumumab) for newly diagnosed patients with multiple myeloma who are transplant ineligible

17 December 2018 - Darzalex combination therapy significantly reduced the risk of disease progression or death compared to a preferred regimen ...

Read more →

Health Canada grants market authorisation for Orkambi (lumacaftor/ivacaftor) for children with cystic fibrosis aged 2 to 5 years old with most common form of the disease

13 December 2018 - Orkambi is the first medicine in Canada to treat the underlying cause of cystic fibrosis in young ...

Read more →

Zaxine (rifaximin) - now indicated in Canada for patients with irritable bowel syndrome with diarrhoea

6 December 2018 - Lupin Pharma Canada is pleased to announce the approval from Health Canada for Zaxine 550 mg (rifaximin) ...

Read more →

Ultragenyx and Kyowa Kirin announce Health Canada approval of Crysvita (burosumab injection) for the treatment of X–linked hypophosphataemia in adults and children

6 December 2018 - First approved treatment for XLH in Canada that targets the underlying cause of this rare, hereditary, lifelong ...

Read more →

Alberta boy with thyroid cancer runs, plays after taking U.S. approved drug

5 December 2018 - Health Canada is considering approving the oral treatment, larotrectinib. ...

Read more →

Alimera Sciences announces Canadian regulatory approval for Iluvien

26 November 2018 - Alimera Sciences today announced that Health Canada has approved Iluvien for the treatment of diabetic macular oedema.  ...

Read more →

Health Canada has now authorised Adynovate [anti-haemophilic factor (recombinant), PEGylated] in paediatrics for treatment of children under 12 with haemophilia A

26 November 2018 - Canadian children now have access to Adynovate, which offers a twice-weekly prophylaxis dosing schedule and on-demand control ...

Read more →